Atypical neuroleptic malignant syndrome. “Doing more harm than gain”

Authors

  • Khalid Javid Bhat Department of Internal Medicine, ASCOMS & Hospital, Jammu, Jammu & Kashmir, 180017
  • Kamal Kishore Pandita Department of Internal Medicine, ASCOMS & Hospital, Jammu, Jammu & Kashmir, 180017
  • Sanjay Bhat Department of Internal Medicine, ASCOMS & Hospital, Jammu, Jammu & Kashmir, 180017
  • Subhash Chander Gupta Department of Neurology, ASCOMS & Hospital, Jammu, Jammu & Kashmir, 180017

Keywords:

Neuroleptic malignant syndrome, Idiosyncratic, Muscle rigidity

Abstract

Neuroleptic malignant syndrome (NMS) a rare, idiosyncratic, and potentially fatal adverse reaction can be deceptive especially when the hallmark features are lacking. Most diagnostic criteria include fever and muscle rigidity, although NMS may present without either. Delirium, agitation and catatonia can be the earliest features of NMS and in acute care settings, concomitant use of sedatives and anti-psychotics by the attending clinicians may even obscure the sentinel signs of NMS and further aggravate the underlying insult. A strong clinical suspicion based on clinical history is crucial for early diagnosis and treatment and the strict adherence to the classical criteria of NMS may lead to a diagnostic delay and dire consequences for these patients and sometimes this delay can procure death.

Metrics

Metrics Loading ...

References

Mathieu S, Hutchings S, Craig G. Neuroleptic malignant syndrome: severe hyperthermia treated with endovascular cooling. J Intensive Care Society. 2010;11:187-9.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994:739-42.

Shah NN, Fless KG, Litinski M, Rezai F, Yodice PC, Rosenberg H. Atypical Neuroleptic Malignant Syndrome: Pitfalls and Challenges in the Delirious Substance Abuser. O J Anes. 2012;2:53-7.

Ananth J, Parameswaran S, Guatilake S, Burgoyne K, Sidhom T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry. 2004;65:464-70.

Bhanushali MJ, Tuite PJ. The evaluation and management of patients with neuroleptic malignant syndrome. Neurol Clin. 2004;22:389-411.

K. Weibrecht, M. Dayno, C. Darling, Bird SB. Liver Aminotransferases Are Elevated with Rhabdo-myolysis in the Absence of Significant Liver Injury. Journal of Medical Toxicology. 2010;6:294-300.

Dallas P. Seitz. Diagnostic uncertainty in a case of neuroleptic malignant syndrome. CJEM 2005;7:266-72.

Downloads

Published

2017-01-28

How to Cite

Bhat, K. J., Pandita, K. K., Bhat, S., & Gupta, S. C. (2017). Atypical neuroleptic malignant syndrome. “Doing more harm than gain”. International Journal of Research in Medical Sciences, 1(4), 601–603. Retrieved from https://www.msjonline.org/index.php/ijrms/article/view/2683